Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 7962 results

  1. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: 18 June 2025

    NICE guideline
    In development

  2. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  3. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  4. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 19 June 2025

    Technology appraisal guidance
    In development

  5. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]

    In development [GID-TA11616] Expected publication date: 19 June 2025

    Technology appraisal guidance
    In development

  6. Topical antimicrobial dressings for locally infected leg ulcers: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 19 June 2025

    Health technology evaluations
    In development

  7. One-piece closed bags for colostomies: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: 24 June 2025

    Health technology evaluations
    In development

  8. Transcatheter aortic valve implantation for native aortic valve regurgitation

    In development [GID-IPG10357] Expected publication date: 24 June 2025

    Interventional procedures guidance
    In development

  9. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  10. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  11. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  12. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  13. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

    In development [GID-TA11183] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  14. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  15. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

    NICE guideline
    Last updated
    2 October 2023

    Sections for NG127